Raymond James Maintains Strong Buy on Fusion Pharmaceuticals, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Rahul Sarugaser has reaffirmed a Strong Buy rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and increased the price target from $15 to $16.
January 05, 2024 | 7:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Rahul Sarugaser has maintained a Strong Buy rating on Fusion Pharmaceuticals and raised the price target from $15 to $16.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100